The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Cinacalcet HCl, an Oral Calcimimetic Agent for the Treatment of Secondary Hyperparathyroidism in Hemodialysis and Peritoneal Dialysis: A Randomized, Double-Blind, Multicenter Study
Abstract
Management of secondary hyperparathyroidism is challenging with traditional therapy. The calcimimetic cinacalcet HCl acts on the calcium-sensing receptor to increase its sensitivity to calcium, thereby reducing parathyroid hormone (PTH) secretion. This phase 3, multicenter, randomized, placebo-controlled, double-blind study evaluated the efficacy and safety of cinacalcet in hemodialysis (HD) and peritoneal dialysis (PD) patients with PTH > or =300 pg/ml despite traditional therapy. A total of 395 patients received once-daily oral cinacalcet (260 HD, 34 PD) or placebo (89 HD, 12 PD) titrated from 30 to 180 mg to achieve a target intact PTH (iPTH) level of < or =250 pg/ml. During a 10-wk efficacy assessment phase, cinacalcet was more effective than control for PTH reduction outcomes, including proportion of patients with mean iPTH levels < or =300 pg/ml (46 versus 9%), proportion of patients with > or =30% reduction in iPTH from baseline (65 versus 13%), and proportion of patients with > or =20, > or =40, or > or =50% reduction from baseline. Cinacalcet had comparable efficacy in HD and PD patients; 50% of PD patients achieved a mean iPTH < or =300 pg/ml. Cinacalcet also significantly reduced serum calcium, phosphorus, and Ca x P levels compared with control treatment. The most common side effects, nausea and vomiting, were usually mild to moderate in severity and transient. Once-daily oral cinacalcet was effective in rapidly and safely reducing PTH, Ca x P, calcium, and phosphorus levels in patients who received HD or PD. Cinacalcet offers a new therapeutic option for controlling secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid
Brown, E. M., Gamba, G., Riccardi, D., Lombardi, M., Butters, R., Kifor, O., Sun, A., Hediger, M. A., Lytton, J., & Hebert, S. C. (1993) · Nature · doi:10.1038/366575a0 · Cited by 2,643
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
Massry, S. G., Coburn, J. W., Chertow, G. M., Hruska, K. A., Langman, C. B., Malluche, H. H., Martin, K. J., McCann, L. M., McCarthy, J. T., Moe, S. M., et al. (2003) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 2,527
Self-citationGoodman, W. G., Goldin, J., Kuizon, B. D., Yoon, C., Gales, B., Sider, D., Wang, Y., Chung, J., Emerick, A., Greaser, L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422003 · Cited by 2,509
Block, G., Hulbert-Shearon, T., Levin, N., & Port, F. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v31.pm9531176 · Cited by 2,354
Oodman, W. I. G. G., Oldin, J. O. G., Uizon, D. K., Oon, C. H. Y., Ales, B. A. G., Ider, D. O. S., Ang, W. C., Oanie, J., Hung, C., Merick, A. L. E., et al. (2000) · Cited by 2,191
GANESH, S. K., STACK, A. G., LEVIN, N. W., HULBERT-SHEARON, T., & PORT, F. K. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v12102131 · Cited by 1,204
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
Block, G. A., Martin, K. J., de Francisco, A. L. M., Turner, S. A., Avram, M. M., Suranyi, M. G., Hercz, G., Cunningham, J., Abu-Alfa, A. K., Messa, P., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031633 · Cited by 1,139
Cardiac calcification in adult hemodialysis patients
Raggi, P., Boulay, A., Chasan-Taber, S., Amin, N., Dillon, M., Burke, S. K., & Chertow, G. M. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01781-8 · Cited by 1,116
Nussbaum, S. R., Zahradnik, R. J., Lavigne, J. R., Brennan, G. L., Nozawa-Ung, K., Kim, L. Y., Keutmann, H. T., Wang, C. A., Potts, J. T., & Segre, G. V. (1987) · Clinical Chemistry · doi:10.1093/clinchem/33.8.1364 · Cited by 808
The spectrum of bone disease in end-stage renal failure—An evolving disorder
Sherrard, D. J., Hercz, G., Pei, Y., Maloney, N. A., Greenwood, C., Manuel, A., Saiphoo, C., Fenton, S. S., & Segre, G. V. (1993) · Kidney International · doi:10.1038/ki.1993.64 · Cited by 730
Calcimimetics with potent and selective activity on the parathyroid calcium receptor
Nemeth, E. F., Steffey, M. E., Hammerland, L. G., Hung, B. C. P., Van Wagenen, B. C., DelMar, E. G., & Balandrin, M. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.4040 · Cited by 610
Pharmacodynamics of the Type II Calcimimetic Compound Cinacalcet HCl
Nemeth, E. F., Heaton, W. H., Miller, M., Fox, J., Balandrin, M. F., Van Wagenen, B. C., Colloton, M., Karbon, W., Scherrer, J., Shatzen, E., et al. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.057273 · Cited by 369
Martin, K. J., González, E. A., Gellens, M., Hamm, L. L., Abboud, H., & Lindberg, J. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v981427 · Cited by 346
Self-citationCardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism
Ribeiro, S. (1998) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/13.8.2037 · Cited by 332
Rayner, H. C., Pisoni, R. L., Bommer, J., Canaud, B., Hecking, E., Locatelli, F., Piera, L., Bragg-Gresham, J. L., Feldman, H. I., Goodkin, D. A., et al. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg483 · Cited by 317
Goodman, W. G., Hladik, G. A., Turner, S. A., Blaisdell, P. W., Goodkin, D. A., Liu, W., Barri, Y. M., Cohen, R. M., & Coburn, J. W. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1341017 · Cited by 281
Self-citationQuarles, L. D., Sherrard, D. J., Adler, S., Rosansky, S. J., McCary, L. C., Liu, W., Turner, S. A., & Bushinsky, D. A. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000050224.03126.ad · Cited by 248
A General Overview of Mantel-Haenszel Methods: Applications and Recent Developments
Kuritz, S. J., Landis, J. R., & Koch, G. G. (1988) · Annual Review of Public Health · doi:10.1146/annurev.pu.09.050188.001011 · Cited by 248
Locatelli, F. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.5.723 · Cited by 203
Allosteric Activation of the Ca2+ Receptor Expressed in Xenopus laevis Oocytes by NPS 467 or NPS 568
Hammerland, L. G., Garrett, J. E., Hung, B. C. P., Levinthal, C., & Nemeth, E. F. (1998) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)13280-4 · Cited by 129
Cited by
Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis
The EVOLVE Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205624 · Cited by 971
Fraser, W. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60507-9 · Cited by 934
Cunningham, J., Danese, M., Olson, K., Klassen, P., & Chertow, G. M. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00596.x · Cited by 566
Self-citationClinical Practice Guideline for the Management of Chronic Kidney Disease‐Mineral and Bone Disorder
Fukagawa, M., Yokoyama, K., Koiwa, F., Taniguchi, M., Shoji, T., Kazama, J. J., Komaba, H., Ando, R., Kakuta, T., Fujii, H., et al. (2013) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12058 · Cited by 402
Microalbuminuria as an Early Marker for Cardiovascular Disease
de Zeeuw, D., Parving, H.-H., & Henning, R. H. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050517 · Cited by 399
Metadata
- Authors
- Lindberg, J. S., Culleton, B., Wong, G., Borah, M. F., Clark, R. V., Shapiro, W. B., Roger, S. D., Husserl, F. E., Klassen, P. S., Guo, M. D., Albizem, M. B., & Coburn, J. W.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2005-03
- Volume
- 16
- Issue
- 3
- Pages
- 800-807
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2126830988
- Cited by
- 413
- References
- 20
- FWCI
- 22.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.